Table 1 Patient characteristics
Subject | Age (years) | Gender | Reason of admission | Use of sedation | Baseline ventilator settings | Days of MV | RASS | pH | PaCO2 (mmHg) | |
|---|---|---|---|---|---|---|---|---|---|---|
PS level (cmH2O) | PEEP level (cmH2O) | |||||||||
1 | 65 | M | Postoperative after AAA | Haloperidol, sufentanil, midazolam | 10 | 10 | 8 | − 1 | 7.41 | 37.5 |
2 | 64 | F | COPD Gold I | Haloperidol | 10 | 8 | 27 | 0 | 7.43 | 51.0 |
3 | 70 | M | Bilateral pneumonia | Haloperidol | 10 | 6 | 22 | − 2 | 7.42 | 58.5 |
4 | 68 | M | Hypoxemia, suspected aeCOPD | Haloperidol | 10 | 5 | 28 | 0 | 7.49 | 40.5 |
5 | 67 | M | CABG | Haloperidol, dexmedetomidine, sufentanil | 10 | 10 | 21 | 0 | 7.50 | 41.3 |
6 | 71 | M | COPD Gold III | Oxazepam | 10 | 5 | 45 | 0 | 7.45 | 64.5 |
7 | 69 | M | CABG, PJP | – | 8 | 6 | 11 | − 1 | 7.42 | 58.5 |
8 | 68 | M | Pneumonia, COPD Gold III | Haloperidol, sufentanil | 10 | 5 | 3 | − 3 | 7.48 | 32.3 |
9 | 65 | M | CABG | Haloperidol, sufentanil | 10 | 6 | 19 | 0 | 7.52 | 36.0 |
10 | 46 | M | Bentall procedure | Midazolam, sufentanil | 10 | 8 | 3 | − 4 | 7.36 | 38.3 |
11 | 62 | M | Septic profile, ARDS | Haloperidol, oxazepam, sufentanil | 10 | 6 | 15 | NA | 7.44 | 35.3 |
12 | 59 | F | COPD Gold II | Remifentanil | 10 | 5 | 7 | NA | 7.43 | 42.8 |
13 | 65 | F | aeCOPD Gold III | Midazolam, sufentanil | 10 | 5 | 8 | − 2 | 7.48 | 51.0 |
14 | 75 | F | Hypercapnic coma, weaning problems | – | 0 | 10 | 20 | 0 | 7.42 | 50.3 |
15 | 52 | M | Mediastinitis, COPD Gold II | Haloperidol | 0 | 8 | 35 | − 2 | NA | NA |
16 | 69 | M | aeCOPD Gold III | Haloperidol, midazolam, sufentanil | 10 | 5 | 3 | − 2 | 7.45 | 42.0 |
17 | 47 | F | Weaning problems | – | 8 | 5 | 20 | 0 | 7.41 | 67.5 |